Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05363046 · ClinicalTrials.gov registry record

Noninterventional Study Evaluating Parkinson's Disease Diary Use

A clinical trial of Parkinson's Disease, sponsored by BlueRock Therapeutics.

Active
Registry status
194
Enrollment target
20
Study locations

NCT05363046: Active study of Parkinson's Disease, sponsored by BlueRock Therapeutics.

NCT05363046 is a study of Parkinson's Disease that is active but no longer recruiting, run by BlueRock Therapeutics. The registered enrollment target is 194 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05363046, a study of Parkinson's Disease, is active but no longer recruiting, sponsored by BlueRock Therapeutics.

ACTIVE NOT RECRUITING
Registry status
194 participants
Enrollment target
20
Study locations

Study Summary

This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.

Primary Outcome

Standard deviation of change in ON-time without troublesome dyskinesia (Good ON-time) as measured by the PD diary.

Conditions Studied

Parkinson's Disease

Study Locations (20)

New York

  • Mount Sinai West - New York
  • Weill Cornell Medicine - New York Presbyterian Hospital - New York
  • University of Rochester Medical Center - Rochester

California

  • David Geffen School of Medicine University of California Los Angeles - Los Angeles
  • University of California, Irvine - Orange

Florida

  • Movement Disorders Center of Boca Raton - Boca Raton
  • University of Miami Health System - Miami

Bavaria

  • Klinikum der Universität München - Campus Grosshadern - Munich
  • Technischen Universitaet Muenchen (TUM) - Munich

Arizona

  • Mayo Clinic Neurology - Scottsdale

Colorado

  • University of Colorado - Aurora

Illinois

  • Parkinson's Disease and Movement Disorders Center at Northwestern University Feinberg School of Medicine - Chicago

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2022-07-29
Est. Completion 2026-10
BlueRock Therapeutics

4 total trials

What the registry record for NCT05363046 still lists

NCT05363046 is an observational study that tracks outcomes without assigning an intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05363046 names 20 study sites across 15 states, led by New York, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05363046 about?

NCT05363046 is a clinical study titled "Noninterventional Study Evaluating Parkinson's Disease Diary Use". This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.

What is the current status of trial NCT05363046?

This trial is currently active not recruiting. The enrollment target is 194 participants. The study started on 2022-07-29. Estimated completion is 2026-10.

What conditions does trial NCT05363046 study?

This clinical trial studies the following conditions: Parkinson's Disease.

Who is sponsoring clinical trial NCT05363046?

This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05363046 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05363046's enrollment target sits among peer trials

194 36th of 158 higher than 123 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03593759 · 194 participants · Phase 3

    Cardiac Sarcoidosis Randomized Trial

  • NCT05053152 · 194 participants · Phase 2

    Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  • NCT05156112 · 194 participants · NA

    OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit

  • NCT05351424 · 194 participants · NA

    AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05363046, the US trial registry maintained by the National Library of Medicine. NCT05363046 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.